A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H Moskowitz; Stephen D Nimer; Andrew D Zelenetz; Tania Trippett; Eric E Hedrick; Daniel A Filippa; Diane Louie; Maria Gonzales; Janine Walits; Nancy Coady-Lyons; Jing Qin; Richard Frank; Joseph R Bertino; Andre Goy; Ariela Noy; James P O'Brien; David Straus; Carol S Portlock; Joachim Yahalom

doi:10.1182/blood.V97.3.616

$A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model$

Journal article

Peer reviewed

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H Moskowitz, Stephen D Nimer, Andrew D Zelenetz, Tania Trippett, Eric E Hedrick, Daniel A Filippa, Diane Louie, Maria Gonzales, Janine Walits, Nancy Coady-Lyons, …

Blood, Vol.97(3), pp.616-623

2001-02-01

DOI: https://doi.org/10.1182/blood.V97.3.616

PMID: 11157476

Abstract

Abstract Salvage of patients with relapsed and refractory Hodgkin disease (HD) with high-dose chemoradiotherapy (HDT) and autologous stem cell transplantation (ASCT) results in event-free survival (EFS) rates from 30% to 50%. Unfortunately, the reduction in toxicity associated with modern supportive care has improved EFS by only 5% to 10% and has not reduced the relapse rate. Results of a comprehensive 2-step protocol encompassing dose-dense and dose-intense second-line chemotherapy, followed by HDT and ASCT, are reported. Sixty-five consecutive patients, 22 with primary refractory HD and 43 with relapsed HD, were treated with 2 biweekly cycles of ifosfamide, carboplatin, and etoposide (ICE). Peripheral blood progenitor cells from responding patients were collected, and the patients were given accelerated fractionation involved field radiotherapy (IFRT) followed by cyclophosphamide-etoposide and either intensive accelerated fractionation total lymphoid irradiation or carmustine and ASCT. The EFS rate at a median follow-up of 43 months, as analyzed by intent to treat, was 58%. The response rate to ICE was 88%, and the EFS rate for patients who underwent transplantation was 68%. Cox regression analysis identified 3 factors before the initiation of ICE that predicted for outcome: B symptoms, extranodal disease, and complete remission duration of less than 1 year. EFS rates were 83% for patients with 0 to 1 adverse factors, 27% for patients with 2 factors, and 10% for patients with 3 factors (P < .001). These results compare favorably with other series and document the feasibility and efficacy of giving uniform dose-dense and dose-intense cytoreductive chemotherapy and integrating accelerated fractionation radiotherapy into an ASCT treatment program. This prognostic model provides a basis for risk-adapted HDT.

Metrics

15 Record Views

321 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.132 Lymphoma
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
Creators: Craig H Moskowitz - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Stephen D Nimer - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Andrew D Zelenetz - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Tania Trippett - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Eric E Hedrick - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Daniel A Filippa - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Diane Louie - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Maria Gonzales - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Janine Walits - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Nancy Coady-Lyons - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Jing Qin - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Richard Frank - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Joseph R Bertino - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Andre Goy - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Ariela Noy - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
James P O'Brien - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
David Straus - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Carol S Portlock - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Joachim Yahalom - From the Lymphoma and Hematology Disease Management Teams, Departments of Medicine, Radiation Oncology, Pathology, Biostatistics, and Pediatrics, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Publication Details: Blood, Vol.97(3), pp.616-623
Academic Unit: Leadership Department; Miller School of Medicine; Sylvester Comprehensive Cancer Center; UMMG Department of Medicine
Language: English
Resource Type: Journal article
PMID: 11157476
Record Identifier: 991031561874902976